CP-88
What is it?
Experimental cyclic peptidomimetic cyclo-{E(I)-E(W)}Na studied in mouse and laboratory hematopoietic assays. Human efficacy and safety are not established here.
Research context
Experimental cyclic peptidomimetic cyclo-{E(I)-E(W)}Na studied in mouse and laboratory hematopoietic assays. Human efficacy and safety are not established here.
- Working classification
- Peptide / preparation research
- Research collection
- Peptide bioregulation · editorial grouping
- Institutional provenance
- Not established for this compound record
- Last evidence review
- Full evidence review pending; source-check scope appears with each publication below.
What do we know?
- Human research
- —See preparation-specific records; human benefit not established here
- Study methods
- —Source-specific designs and limitations below
- Independent replication
- —Related reports are not automatically independent evidence
- Source access
- —Linked publications; access and review scope shown per record
- Safety evidence
- —Clinical safety, product equivalence and interactions not established by this collection
These are independent review fields, not a rating. Missing evidence in this starter does not mean no research exists.
Explore the expanded peptide research collection and unresolved source trails ↗
Linked sources
Explore the research map and unresolved leads ↗
Novel Peptidomimetic Cyclo-{E(I)-E(W)}Na (CP-88) with Hematopoietic Activity Sustained in Invasive and Oral Administration: Experimental and Preclinical Evaluation
Defined synthetic peptide / analogue
Vladislav Deigin, Yulia Vinogradova, Dmitriy Vinogradov, Natalia Linkova, Anastasiia Dyatlova, Dmitrii Medvedev, Alexander Krasichkov, Victoria Polyakova · International Journal of Molecular Sciences 25(24):13385
Mouse and laboratory experiments report colony-forming activity, CD34-positive-cell changes and NF-κB reporter activation. These do not establish long-term stem-cell self-renewal, direct Toll-like-receptor binding or a causal NF-κB mechanism. Oral experimental activity does not establish human pharmacokinetics; preclinical safety extrapolations are not safe human doses.
- Population / setting
- Source-specific experimental population
- What was checked
- Original full text retrieved from Europe PMC; experimental scope and interpretation checked. Supplementary methods and independent replication remain review targets.
Limitations & review scope
- Independent replication and full risk-of-bias appraisal remain unresolved.
- No personalized treatment or safety conclusion follows from this record.
Source checked 2026-10-02. This is a source-linked record, not a completed evidence review.